DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,889,361 B2 Chen (45) Date of Patent: Nov

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,889,361 B2 Chen (45) Date of Patent: Nov USOO888.9361 B2 (12) United States Patent (10) Patent No.: US 8,889,361 B2 Chen (45) Date of Patent: Nov. 18, 2014 (54) GENE EXPRESSION SIGNATURES IN FOREIGN PATENT DOCUMENTS ENRICHED TUMIOR CELL SAMPLES WO WO-2005049168 A2 * 6, 2005 WO WO-2006042005 A2 * 4, 2006 (75) Inventor: Wen-Tien Chen, Stonybrook, NY (US) OTHER PUBLICATIONS (73) Assignee: The Research Foundation for The Strausberg et al., in Microarrays and Cancer Research, 2002, War State University of New York, Albany, rington etal (eds.), Eaton Publishing, Westborough, MA, pp. xi-xvi.* NY (US) Notterman et al., in Microarrays and Cancer Research, 2002, War rington et al (eds.), Eaton Publishing, Westborough, MA, pp. (*) Notice: Subject to any disclaimer, the term of this 81-111. patent is extended or adjusted under 35 Balzar, M. etal. The biology of the 17-1A antigen (Ep-CAM), J Mol U.S.C. 154(b) by 867 days. Med, (1999), vol. 77, pp. 699-712. FeeZor, R.J. et al., Significance of Micrometastases in Colorectal Cancer, Annals of Surgical Oncology, (2002), vol. 9, No. 10, pp. (21) Appl. No.: 12/678,921 944-953. Brandt, B.H. et al., Predictive laboratory diagnostics in oncology (22) PCT Filed: Sep.19, 2008 utilizing blood-borne cancer cells—current best practice and unmet needs, Cancer Letters, (2001), vol. 162, pp. S11-S16. (86). PCT No.: PCT/US2O08/O10881 Xenidis, N. et al., Clinical relevance of circulating CK-19 mRNA positive cells detected during the adjuvant tamoxifen treatment in S371 (c)(1), patients with early breast cancer, Annals of Oncology, (2007), vol. (2), (4) Date: Aug. 10, 2010 18, pp. 1623-1631. Xenidis, N. et al., Predictive and prognostic value of peripheral blood Cytokeratin-19 mRNA-Positive Cells Detected by Real-Time (87) PCT Pub. No.: WO2009/038754 Polymerase chain Reaction in Node-Negative Breast Cancer PCT Pub. Date: Mar. 26, 2009 Patients, Journal of Clinical Oncology, (Aug. 10, 2006), vol. 24. No. 23, pp. 3756-3762. (65) Prior Publication Data Chen, W., Proteolytic Activity of Specialized Surface Protrusions Formed at Rosette Contact Sites of Transformed Cells, The Journal of US 2010/O297634 A1 Nov. 25, 2010 Experimental Zoology, (1989), vol. 251, pp. 167-185. Chen, W. et al., Local degradation offibronectin at sites of expression of the transforming gene product pp60, Nature, (Jul 11, 1985), vol. 316, pp. 156-158. Related U.S. Application Data Chen, W. et al., Expression of tau exon 8 in different species, Neuroscience Letters, (1994), vol. 172, pp. 167-170. (60) Provisional application No. 60/994,592, filed on Sep. Chen, W. et al., Membrane proteases as potential diagnostic and 19, 2007. therapeutic targets for breast malignancy, Breast Cancer Research and Treatment, (1994), vol. 31, pp. 217-226. (51) Int. Cl. Chen, W. Proteases Associated with Invadopodia, and Their Role in CI2O I/68 (2006.01) Degradation of Extracellular Matrix, Enzyme Protein, (1996), vol. (52) U.S. Cl. 49, pp. 59-71. Friedl, P. et al., Tumour-Cell Invasion and Migration: Diversity and CPC ........ CI2O I/6886 (2013.01); C12O 2600/1 12 Escape Mechanisms, Nat Rev Cancer, (2003), vol. 3, pp. 362-374. (2013.01); C12O 2600/158 (2013.01) Goldstein, L.A. et al., Molecular cloning of seprase: a serine integral USPC ......................................................... 435/6.14 membrane protease from human melanoma, Biochimica et (58) Field of Classification Search Biophysica Acta, (1997), vol. 1361, pp. 11-19. None Xi, L. et al., Optimal Markers for Real-Time Quantitative Reverse Transcription PCR Detection of Circulating Tumor Cells from Mela See application file for complete search history. noma, Breast, Colon, Esophageal, Head and Neck, and Lung Can cers, Clinical Chemistry, (2007), vol. 53, No. 7, pp. 1206-1215. (56) References Cited Iakovlev, V.V.. et al., Quantitative detection of circulating epithelial cells by Q-RT-PCR. Breast Cancer Res Treat, (2008), vol. 107, pp. U.S. PATENT DOCUMENTS 145-154. Matsunami, K. et al., Detection of Bone Marrow Micrometastis in 4,683, 195 A 7, 1987 Mullis et al. Gastric Cancer Patients by Immunomagnetic Separation, Annals of 4,683.202 A 7, 1987 Mullis Surgical Oncology, (2003), vol. 10, No. 2, pp. 171-175. 4,965,188 A 10, 1990 Mullis et al. 4,981,785 A 1/1991 Nayak (Continued) 5,358,691 A 10, 1994 Clarket al. 5,599,677 A 2f1997 Dowell et al. Primary Examiner — James Martinell 5,672,480 A 9, 1997 Dowell et al. (74) Attorney, Agent, or Firm — Scully, Scott, Murphy & 5,885,530 A 3, 1999 Babson et al. 6,159,750 A 12/2000 Edmonds Presser, P.C. 2002fO164825 A1 11/2002 Chen (57) ABSTRACT 2003/0206901 A1 11/2003 Chen 2004/0110227 A1* 6/2004 Levanon et al. ............... 435.7.1 The invention is embodied in methods for finding gene 2005. O153342 A1 7, 2005 Chen expression signatures of circulating melanoma cells, ovarian, 2005/0244843 A1 11/2005 Chen et al. breast, colorectal cancer cells, and circulating endothelial 2005/0250 148 A1* 1 1/2005 Bevilacqua et al. .............. 435/6 progenitor cells, which signatures are effective in distinguish 2005/02594.83 A1* 11/2005 Nakamura et al. ....... 365, 18907 ing the circulating cancer cell from normal circulating cells 2005/0260639 A1* 11/2005 Nakamura et al. ................ 435/6 and can also distinguish between different types of circulat 2005/0272103 A1 12, 2005 Chen 2006/0134653 A1* 6/2006 Burgess et al. ................... 435/6 ing cancer cells. 2006/0204960 A1* 9/2006 Nakamura et al. ................ 435/6 8 Claims, 22 Drawing Sheets US 8,889,361 B2 Page 2 (56) References Cited Coopman, P.J. et al., Integrino.3 B1 Participates in the Phagocytosis of Extracellular Matrix Molecules by Human Breast Cancer Cells, OTHER PUBLICATIONS Molecular Biology of the Cell, (Nov. 1996), vol. 7, pp. 1789-1804. Monsky, W. L. et al., A Potential Marker Protease of Invasiveness, Cristofanilli, M. et al., Circulating Tumor Cells, Disease Progression, Seprase, Is Localized on Invadopodia of Human Malignant Mela and Survival in Metastatic Breast Cancer, New England Journal of noma Cells, Cancer Research, (Nov. 1, 1994), vol. 54, pp. 5702-5710. Medicine, (Aug. 19, 2004), vol. 351, No. 8, pp. 781-791. Yao, J. et al., Combined cDNA Array Comparative Genomic Hybrid De Kok, J.B. et al., Normalization of gene expression measurements ization and Serial Analysis of Gene Expression Analysis of Breast in tumor tissues: comparison of 13 endogenous control genes, Labo Tumor Progression, Cancer Res, (2006), vol. 66, pp. 4065-4078. ratory Investigation, (2005), vol. 85, pp. 154-159. Pantel, K. et al., Detection, clinical relevance and specific biological Fehm, T. et al., Cytogenetic Evidence That Circulating Epithelial properties of disseminating tumour cells, Nature Reviews, (May Cells in Patients with Carcinoma Are Malignant, Clin Cancer Res, 2008), vol. 8, pp. 329-340. (2002), vol. 8, pp. 2073-2084. Zucker, S. et al., Critical appraisal of the use of matrix metal Flatmark, K. et al., Immunomagnetic Detection of Micrometastatic loproteinase inhibitors in cancer treatment, Oncogene, (2000), vol. Cells in Bone Marrow of Colorectal Cancer Patients, Clin Cancer 19, pp. 6642-6650. Res, (2002), vol. 8, pp. 444-449. Xenidis, N. et al., Peripheral blood circulating cytokeratin-19 Ghersi, G. et al., Regulation of fibroblast migration on collagenous mRNA-positive cells after the completion of adjuvant chemotherapy matrix by a cell surface peptidase complex, J. Biol. Chem... (2002), in patients with operable breast cancer, Annals of Oncology, (2003), vol. 277, No. 32, pp. 29231-29241. vol. 14, pp. 849-855. Glaves, D. et al., Correlation between circulating cancer cells and Sawyers, C.L. et al., The cancer biomarker problem, Nature, (Apr. 3, incidence of metastases, Br. J. Cancer, (1983), vol. 48, pp. 665-673. 2008) vol. 452, pp. 548-552. Goldstein, L.A. et al., Identification of an Alternatively Spliced Tsuda, H. et al., Identification of DNA copy number changes in Seprase mRNA That Encodes a Novel Intracellular Isoform, J. Biol. microdissected serous ovarian cancer tissue using a cDNA microar Chem. (2000), vol. 275, pp. 2554-2559. ray platform, Cancer Genetics and Cytogenetics, (2004), vol. 155, pp. Goto, T. et al., Gene expressionprofiles with cDNA microarray reveal 97-107. RhoGDI as a predictive marker for paclitaxel resistance in ovarian Winter, M.J. et al., The Epithelial Cell Adhesion Molecule (Ep cancers, Oncology Reports, (2006), vol. 15, pp. 1265-1271. CAM) as a Morphoregulatory Molecule Is a Tool in Surgical Pathol Gross, H. et al., Model study detecting breast cancer cells in periph ogy, (Dec. 2003), vol. 163, No. 6, pp. 2139-2148. eral blood mononuclear cells at frequencies as low as 10-7. Proc. Wilhelm, M.C. et al., Nonpalpable Invasive Breast Cancer, Ann Natl. Acad. Sci. USA, (Jan. 1995), vol. 92, pp. 537-541. Surg., (1991), vol. 213, No. 6, pp. 600-605. Hill, J.M. et al., Circulating Endothelial Progenitor Cells, Vascular Adib, T.R. et al., Predicting biomarkers for ovarian cancer using Function, and Cardiovascular Risk, New England Journal of Medi gene-expression microarrays, British Journal of Cancer, (2004), vol. cine, (Feb. 13, 2003), vol. 348, No. 7, pp. 593-600. 90, pp. 686-692. Hough, C.D. et al., Large-Scale Serial Analysis of Gene Expression Allard, W.J. et al., Tumor Cells Circulate in the Peripheral Blood of Reveals Genes Differentially Expressed in Ovarian Cancer, Cancer All Major carcinomas but not in Healthy Subjects or Patients With Res, (2000), vol. 60, pp. 6281-6287. Nonmalignant Diseases, Clin Cance Res, (2004), vol. 10, pp. 6897 Ignatiadis, M. et al., Prognostic Value of the Molecular Detection of 6904. Circulating Tumor Cells Using a Multimarker Reverse Transcription Allard, W.J. et al., Tumor Cells Circulate in the Peripheral Blood of PCRAssay for Cytokeratin 19, Mammaglobin A, and HER2 in Early All Major carcinomas but not in Healthy Subjects or Patients With Breast Cancer, Clin Cancer Res, (2008), vol.
Load more

Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • Tools for Cell Therapy and Immunoregulation
    RnDSy-lu-2945 Tools for Cell Therapy and Immunoregulation Target Cell TIM-4 SLAM/CD150 BTNL8 PD-L2/B7-DC B7-H1/PD-L1 (Human) Unknown PD-1 B7-1/CD80 TIM-1 SLAM/CD150 Receptor TIM Family SLAM Family Butyrophilins B7/CD28 Families T Cell Multiple Co-Signaling Molecules Co-stimulatory Co-inhibitory Ig Superfamily Regulate T Cell Activation Target Cell T Cell Target Cell T Cell B7-1/CD80 B7-H1/PD-L1 T cell activation requires two signals: 1) recognition of the antigenic peptide/ B7-1/CD80 B7-2/CD86 CTLA-4 major histocompatibility complex (MHC) by the T cell receptor (TCR) and 2) CD28 antigen-independent co-stimulation induced by interactions between B7-2/CD86 B7-H1/PD-L1 B7-1/CD80 co-signaling molecules expressed on target cells, such as antigen-presenting PD-L2/B7-DC PD-1 ICOS cells (APCs), and their T cell-expressed receptors. Engagement of the TCR in B7-H2/ICOS L 2Ig B7-H3 (Mouse) the absence of this second co-stimulatory signal typically results in T cell B7-H1/PD-L1 B7/CD28 Families 4Ig B7-H3 (Human) anergy or apoptosis. In addition, T cell activation can be negatively regulated Unknown Receptors by co-inhibitory molecules present on APCs. Therefore, integration of the 2Ig B7-H3 Unknown B7-H4 (Mouse) Receptors signals transduced by co-stimulatory and co-inhibitory molecules following TCR B7-H5 4Ig B7-H3 engagement directs the outcome and magnitude of a T cell response Unknown Ligand (Human) B7-H5 including the enhancement or suppression of T cell proliferation, B7-H7 Unknown Receptor differentiation, and/or cytokine secretion.
    [Show full text]
  • Myosin Myth4-FERM Structures Highlight Important Principles of Convergent Evolution
    Myosin MyTH4-FERM structures highlight important principles of convergent evolution Vicente José Planelles-Herreroa,b, Florian Blanca,c, Serena Sirigua, Helena Sirkiaa, Jeffrey Clausea, Yannick Souriguesa, Daniel O. Johnsrudd, Beatrice Amiguesa, Marco Cecchinic, Susan P. Gilberte, Anne Houdussea,1,2, and Margaret A. Titusd,1,2 aStructural Motility, Institut Curie, CNRS, UMR 144, PSL Research University, F-75005 Paris, France; bUPMC Université de Paris 6, Institut de Formation Doctorale, Sorbonne Universités, 75252 Paris Cedex 05, France; cLaboratoire d’Ingénierie des Fonctions Moléculaires, Institut de Science et d’Ingénierie Supramoléculaires, UMR 7006 CNRS, Université de Strasbourg, F-67083 Strasbourg Cedex, France; dDepartment of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN 55455; and eDepartment of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180 Edited by James A. Spudich, Stanford University School of Medicine, Stanford, CA, and approved March 31, 2016 (received for review January 15, 2016) Myosins containing MyTH4-FERM (myosin tail homology 4-band (Fig. 1). These MF myosins are widespread and likely quite an- 4.1, ezrin, radixin, moesin, or MF) domains in their tails are found cient because they are found in many different branches of the in a wide range of phylogenetically divergent organisms, such as phylogenetic tree (5, 6), including Opisthokonts (which includes humans and the social amoeba Dictyostelium (Dd). Interestingly, Metazoa, unicellular Holozoa, and Fungi), Amoebozoa, and the evolutionarily distant MF myosins have similar roles in the exten- SAR (Stramenopiles, Alveolates, and Rhizaria) (Fig. 1 A and B). sion of actin-filled membrane protrusions such as filopodia and Over the course of hundreds of millions years of parallel evolution bind to microtubules (MT), suggesting that the core functions of the MF myosins have acquired or maintained roles in the formation these MF myosins have been highly conserved over evolution.
    [Show full text]
  • Mass Spectrometry-Based Proteomics Techniques and Their Application in Ovarian Cancer Research Agata Swiatly, Szymon Plewa, Jan Matysiak and Zenon J
    Swiatly et al. Journal of Ovarian Research (2018) 11:88 https://doi.org/10.1186/s13048-018-0460-6 REVIEW Open Access Mass spectrometry-based proteomics techniques and their application in ovarian cancer research Agata Swiatly, Szymon Plewa, Jan Matysiak and Zenon J. Kokot* Abstract Ovarian cancer has emerged as one of the leading cause of gynecological malignancies. So far, the measurement of CA125 and HE4 concentrations in blood and transvaginal ultrasound examination are essential ovarian cancer diagnostic methods. However, their sensitivity and specificity are still not sufficient to detect disease at the early stage. Moreover, applied treatment may appear to be ineffective due to drug-resistance. Because of a high mortality rate of ovarian cancer, there is a pressing need to develop innovative strategies leading to a full understanding of complicated molecular pathways related to cancerogenesis. Recent studies have shown the great potential of clinical proteomics in the characterization of many diseases, including ovarian cancer. Therefore, in this review, we summarized achievements of proteomics in ovarian cancer management. Since the development of mass spectrometry has caused a breakthrough in systems biology, we decided to focus on studies based on this technique. According to PubMed engine, in the years 2008–2010 the number of studies concerning OC proteomics was increasing, and since 2010 it has reached a plateau. Proteomics as a rapidly evolving branch of science may be essential in novel biomarkers discovery, therapy decisions, progression predication, monitoring of drug response or resistance. Despite the fact that proteomics has many to offer, we also discussed some limitations occur in ovarian cancer studies.
    [Show full text]
  • Circmyo10 Promotes Osteosarcoma Progression by Regulating Mir-370
    Chen et al. Molecular Cancer (2019) 18:150 https://doi.org/10.1186/s12943-019-1076-1 RESEARCH Open Access CircMYO10 promotes osteosarcoma progression by regulating miR-370-3p/ RUVBL1 axis to enhance the transcriptional activity of β-catenin/LEF1 complex via effects on chromatin remodeling Junxin Chen1†, Gang Liu1†, Yizheng Wu1†, Jianjun Ma1†, Hongfei Wu2, Ziang Xie1, Shuai Chen1, Yute Yang1, Shengyu Wang1, Panyang Shen1, Yifan Fang3, Shunwu Fan1, Shuying Shen1* and Xiangqian Fang1* Abstract Background: CircMYO10 is a circular RNA generated by back-splicing of gene MYO10 and is upregulated in osteosarcoma cell lines, but its functional role in osteosarcoma is still unknown. This study aimed to clarify the mechanism of circMYO10 in osteosarcoma. Methods: CircMYO10 expression in 10 paired osteosarcoma and chondroma tissues was assessed by quantitative reverse transcription polymerase chain reaction (PCR). The function of circMYO10/miR-370-3p/RUVBL1 axis was assessed regarding two key characteristics: proliferation and endothelial–mesenchymal transition (EMT). Bioinformatics analysis, western blotting, real-time PCR, fluorescence in situ hybridization, immunoprecipitation, RNA pull-down assays, luciferase reporter assays, chromatin immunoprecipitation, and rescue experiments were used to evaluate the mechanism. Stably transfected MG63 cells were injected via tail vein or subcutaneously into nude mice to assess the role of circMYO10 in vivo. Results: CircMYO10 was significantly upregulated, while miR-370-3p was downregulated, in osteosarcoma cell lines and human osteosarcoma samples. Silencing circMYO10 inhibited cell proliferation and EMT in vivo and in vitro. Mechanistic investigations revealed that miR-370-3p targets RUVBL1 directly, and inhibits the interaction between RUVBL1 and β-catenin/LEF1 complex while circMYO10 showed a contrary effect via the inhibition of miR-370-3p.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Molecular Pathways Associated with the Nutritional Programming of Plant-Based Diet Acceptance in Rainbow Trout Following an Early Feeding Exposure Mukundh N
    Molecular pathways associated with the nutritional programming of plant-based diet acceptance in rainbow trout following an early feeding exposure Mukundh N. Balasubramanian, Stéphane Panserat, Mathilde Dupont-Nivet, Edwige Quillet, Jérôme Montfort, Aurélie Le Cam, Françoise Médale, Sadasivam J. Kaushik, Inge Geurden To cite this version: Mukundh N. Balasubramanian, Stéphane Panserat, Mathilde Dupont-Nivet, Edwige Quillet, Jérôme Montfort, et al.. Molecular pathways associated with the nutritional programming of plant-based diet acceptance in rainbow trout following an early feeding exposure. BMC Genomics, BioMed Central, 2016, 17 (1), pp.1-20. 10.1186/s12864-016-2804-1. hal-01346912 HAL Id: hal-01346912 https://hal.archives-ouvertes.fr/hal-01346912 Submitted on 19 Jul 2016 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Balasubramanian et al. BMC Genomics (2016) 17:449 DOI 10.1186/s12864-016-2804-1 RESEARCH ARTICLE Open Access Molecular pathways associated with the nutritional programming of plant-based diet acceptance in rainbow trout following an early feeding exposure Mukundh N. Balasubramanian1, Stephane Panserat1, Mathilde Dupont-Nivet2, Edwige Quillet2, Jerome Montfort3, Aurelie Le Cam3, Francoise Medale1, Sadasivam J. Kaushik1 and Inge Geurden1* Abstract Background: The achievement of sustainable feeding practices in aquaculture by reducing the reliance on wild-captured fish, via replacement of fish-based feed with plant-based feed, is impeded by the poor growth response seen in fish fed high levels of plant ingredients.
    [Show full text]
  • Supplementary Table 2A. Proband-Specific Variants Proband
    Supplementary table 2A. Proband-specific variants Proband Gene Gene full name Chr Position RefSeqChange Function ESP6500 1000 Genome SNP137 PolyPhen2 Nucleotide Amino acid Score Prediction 1 AGAP5 ArfGAP with GTPase domain, ankyrin repeat and PH domain 5 chr10 75435178 NM_001144000 c.G1240A p.V414M exonic . 0.99 D 1 REXO1L1 REX1, RNA exonuclease 1 homolog (S. cerevisiae)-like 1 chr8 86574465 NM_172239 c.A1262G p.Y421C exonic . 0.98 D 1 COL4A3 collagen, type IV, alpha 3 (Goodpasture antigen) chr2 228169782 NM_000091 c.G4235T p.G1412V exonic . 1.00 D 1 KIAA1586 KIAA1586 chr6 56912133 NM_020931 c.C44G p.A15G exonic . 0.99 D 1 KIAA1586 KIAA1586 chr6 56912176 NM_020931 c.C87G p.D29E exonic . 0.99 D 1 JAKMIP3 Janus kinase and microtubule interacting protein 3 chr10 133955524 NM_001105521 c.G1574C p.G525A exonic . 1.00 D 1 MPHOSPH8 M-phase phosphoprotein 8 chr13 20240685 NM_017520 c.C2140T p.L714F exonic . 0.97 D 1 SYNE1 spectrin repeat containing, nuclear envelope 1 chr6 152783902 NM_033071 c.A2242T p.N748Y exonic . 0.97 D 1 CAND2 cullin-associated and neddylation-dissociated 2 (putative) chr3 12858835 NM_012298 c.C2125T p.H709Y exonic . 0.95 D 1 TDRD9 tudor domain containing 9 chr14 104460909 NM_153046 c.T1289G p.V430G exonic . 0.96 D 2 ASPM asp (abnormal spindle) homolog, microcephaly associated (Drosophila)chr1 197091625 NM_001206846 c.G3491A p.R1164H exonic . 0.99 D 2 ADAM29 ADAM metallopeptidase domain 29 chr4 175896951 NM_001130705 c.A275G p.D92G exonic . 1.00 D 2 BCO2 beta-carotene oxygenase 2 chr11 112087019 NM_001256398 c.G1373A p.G458E exonic .
    [Show full text]
  • Cellular and Molecular Signatures in the Disease Tissue of Early
    Cellular and Molecular Signatures in the Disease Tissue of Early Rheumatoid Arthritis Stratify Clinical Response to csDMARD-Therapy and Predict Radiographic Progression Frances Humby1,* Myles Lewis1,* Nandhini Ramamoorthi2, Jason Hackney3, Michael Barnes1, Michele Bombardieri1, Francesca Setiadi2, Stephen Kelly1, Fabiola Bene1, Maria di Cicco1, Sudeh Riahi1, Vidalba Rocher-Ros1, Nora Ng1, Ilias Lazorou1, Rebecca E. Hands1, Desiree van der Heijde4, Robert Landewé5, Annette van der Helm-van Mil4, Alberto Cauli6, Iain B. McInnes7, Christopher D. Buckley8, Ernest Choy9, Peter Taylor10, Michael J. Townsend2 & Costantino Pitzalis1 1Centre for Experimental Medicine and Rheumatology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square, London EC1M 6BQ, UK. Departments of 2Biomarker Discovery OMNI, 3Bioinformatics and Computational Biology, Genentech Research and Early Development, South San Francisco, California 94080 USA 4Department of Rheumatology, Leiden University Medical Center, The Netherlands 5Department of Clinical Immunology & Rheumatology, Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands 6Rheumatology Unit, Department of Medical Sciences, Policlinico of the University of Cagliari, Cagliari, Italy 7Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow G12 8TA, UK 8Rheumatology Research Group, Institute of Inflammation and Ageing (IIA), University of Birmingham, Birmingham B15 2WB, UK 9Institute of
    [Show full text]
  • CDH12 Cadherin 12, Type 2 N-Cadherin 2 RPL5 Ribosomal
    5 6 6 5 . 4 2 1 1 1 2 4 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 2 2 A A A A A A A A A A A A A A A A A A A A C C C C C C C C C C C C C C C C C C C C R R R R R R R R R R R R R R R R R R R R B , B B B B B B B B B B B B B B B B B B B , 9 , , , , 4 , , 3 0 , , , , , , , , 6 2 , , 5 , 0 8 6 4 , 7 5 7 0 2 8 9 1 3 3 3 1 1 7 5 0 4 1 4 0 7 1 0 2 0 6 7 8 0 2 5 7 8 0 3 8 5 4 9 0 1 0 8 8 3 5 6 7 4 7 9 5 2 1 1 8 2 2 1 7 9 6 2 1 7 1 1 0 4 5 3 5 8 9 1 0 0 4 2 5 0 8 1 4 1 6 9 0 0 6 3 6 9 1 0 9 0 3 8 1 3 5 6 3 6 0 4 2 6 1 0 1 2 1 9 9 7 9 5 7 1 5 8 9 8 8 2 1 9 9 1 1 1 9 6 9 8 9 7 8 4 5 8 8 6 4 8 1 1 2 8 6 2 7 9 8 3 5 4 3 2 1 7 9 5 3 1 3 2 1 2 9 5 1 1 1 1 1 1 5 9 5 3 2 6 3 4 1 3 1 1 4 1 4 1 7 1 3 4 3 2 7 6 4 2 7 2 1 2 1 5 1 6 3 5 6 1 3 6 4 7 1 6 5 1 1 4 1 6 1 7 6 4 7 e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e e l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l l p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p p m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m m
    [Show full text]
  • 140503 IPF Signatures Supplement Withfigs Thorax
    Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network.
    [Show full text]
  • Supplementary Table 5. Functional Annotation of the Largest Gene Cluster(221 Element)
    Annotation Tool AFFYID VALUE SYMBOL LOCUSLINK OMIM GENENAME GENEONTOLOGY SUMMARY [Proteome FUNCTION:] Expressed 203054_s_at TCTA 6988 600690 T-cell leukemia translocation altered gene tumor suppressor ubiquitously [Proteome FUNCTION:] May be involved in protein-protein interactions; contains five WD 44563_at FLJ10385 55135 hypothetical protein FLJ10385 domains (WD-40 repeats) [Proteome FUNCTION:] Weakly similarity to 212261_at TNRC15 26058 trinucleotide repeat containing 15 a region of rat nestin (Rn.9701) [SUMMARY:] Actin alpha 1 which is expressed in skeletal muscle is one of six different actin isoforms which have been identified. Actins are highly conserved proteins that are involved in cell motility, actin filament; motor activity; muscle structure and integrity. Alpha actins are a contraction; muscle development; structural major constituent of the contractile 203872_at ACTA1 58 102610 actin, alpha 1, skeletal muscle constituent of cytoskeleton apparatus. [SUMMARY:] Annexin VIII belong to the family of Ca (2+) dependent phospholipid binding proteins (annexins), and has a high 56% identity to annexin V (vascular anticoagulant-alpha). It was initially isolated as 2.2 kb vascular anticoagulant-beta transcript from human placenta, a Ca (2+) dependent phospholipid binding protein that inhibits coagulation and phospholipase A2 activity. However, the fact that annexin VIII is neither an extracellular protein nor associated with the cell surface suggests that it may not play a role in blood coagulation in vivo and its physiological role remains unknown. It is expressed at low levels in human placenta and shows restricted expression in lung endothelia, skin, liver, and kidney. The gene is also found to be selectively overexpressed in acute 203074_at ANXA8 244 602396 annexin A8 myelocytic leukemia.
    [Show full text]